

(Invitrogen), and cDNA was synthesized and amplified using an ExScript™ RT Reagent Kit. Quantification of TNF- α mRNA was performed by real-time polymerase chain reaction (PCR) detection, using an ABI PRISM 7000 sequence detection system (Applied Biosystems) and SYBR Green detection of the amplification products. The copy numbers of the transcripts were measured against copy-number standard curves for the cloned target templates consisting of 10-fold serial dilution points. The amplification mixtures contained 10 μ L of 2 \times SYBR Premix Ex Taq™, 1 μ L of cDNA synthesis mixture, 4 pmol each of the forward and reverse primers, and distilled water in a total volume of 20 μ L. The *mTNF- α* primers used were as follows: forward: 5'-ACAAGGCTGCCCCGACTAC-3' and reverse: 5'-TTTCTCCTGGTATGAGATAGCAAATC-3'. All mRNA expression levels were normalized to the levels of β -actin.

MTX Dosing Time-Dependent Change in Serum Amyloid A (SAA), Immunoglobulin G-Rheumatoid Factor (IgG-RF), and TNF- α Concentrations in MRL/lpr Mice

Based on the 24-h rhythm of TNF- α mRNA level (see Figure 1), MTX (10 mg/kg) was administered to 10-wk-old MRL/lpr mice ($n = 8$) three times/wk for 2 wks (total of 60 mg/kg of MTX) at 6 or 18 HALO when the TNF- α level begins to decrease or increase. Sodium bicarbonate (7%) was administered to the control group ($n = 14$ or 15). On day 14, blood was taken at 2 HALO, and the samples were immediately centrifuged at 3,000 rpm for 15 min. Plasma was stored at -80°C until analyzed.

Measurement of SAA, IgG-RF, and TNF- α Levels in Blood

SAA and IgG-RF were measured using a Mouse SAA ELISA (enzyme-linked immunosorbent assay) kit (SW type) and a Mouse IgG Rheumatoid Factor ELISA kit




FIGURE 1. Twenty-four-hour rhythms of TNF- α mRNA in 10- (○) and 15- (◆) wk-old MRL/lpr mice. The relative expression levels of TNF- α mRNA compared to those of β -actin are shown. Each value represents the mean and SD of five to seven mice. * $p < .05$ and ** $p < .01$ compared to the 10-wk-old group. TNF- α mRNA levels in leukocytes showed a clear 24-h rhythm with higher levels at 22 HALO and lower levels at 18 HALO in the 15-wk-old group (F from ANOVA = 3.55, $p < .05$; p from cosinor = .06).

© Informa Healthcare USA, Inc.

(Shibayagi, Japan). Multianalyte profiling was performed using the Luminex-100 system (Luminex). The acquired fluorescence data were analyzed using MasterPlex QT software (Ver. 1.2; MiraiBio). Plasma TNF- α concentrations were determined using the Mouse Inflammatory Cytokine 4-Plex kit (Biosource). All analyses were performed according to the manufacturers' protocols.

Clinical Trial

The clinical trial was a prospective, single-arm study to assess the effects and safety of MTX chronotherapy in RA patients. In the chronotherapy, the dose and number of doses/wk were not changed from the original MTX dosing schedule of each patient, but MTX was orally administered once-a-day, always at bedtime. Patients were scheduled for routine follow-up clinic visits in wks 4, 8, and 12 of chronotherapy, and efficacy and safety-related assessments were performed. The primary endpoints were changes in the DAS28 and leukocyte count from the baseline (wk 0) to 3 mos of chronotherapy. The secondary endpoints included tender and swollen joint counts, the patients' assessment of their overall disease activity, modified health assessment questionnaire (MHAQ), and the C-reactive protein (CRP), SAA, matrix metalloproteinase (MMP)-3, RF, TNF- α , and interleukin (IL)-6 levels in serum.

DAS28 is a composite score based on tender and swollen joint counts (28 joints), the patient's global assessment of their disease activity (100 mm Visual Analog Scale [VAS]: 0 = no activity, 100 = extreme activity). DAS28 values were calculated as follows:

$$\text{DAS28 (CRP)} = 0.56 \times \sqrt{(\text{TJC28})} + 0.28 \times \sqrt{(\text{SJC28})} + 0.014 \times \text{GH} + 0.36 \times \ln(\text{CRP} + 1) + 0.96$$

where TJC = tender joint count, SJC = swollen joint count, GH = general health, and CRP = C-reactive protein in mg/dL. A score of ≥ 5.1 indicates high disease activity, a score > 3.2 and ≤ 5.1 indicates moderate disease activity, a score < 3.2 indicates low disease activity, and a score < 2.6 indicates disease remission (van Gestel et al., 1996). The European league against rheumatism (EULAR) response states were classified as follows: good responders were patients displaying an improvement of > 1.2 and a present score of ≤ 3.2 ; moderate responders were patients displaying an improvement of > 0.6 and ≤ 1.2 and a present score of ≤ 5.1 , or an improvement of > 1.2 and a present score of > 3.2 ; and nonresponders were any patients displaying an improvement of ≤ 0.6 , or patients displaying an improvement of > 0.6 and ≤ 1.2 and a present score of > 5.1 (Fransen & van Riel, 2005).

Myelosuppression was evaluated according to the Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE 3.0). Leukocyte counts were graded as: 1 (3500–3000 cells/mm³), 2 (2999–2000 cells/mm³), 3 (1999–1000 cells/mm³), or 4 (< 1000 cells/mm³).

MHAQ assesses the ability of patients to perform daily activities using eight questions. The final MHAQ score is the mean score of the eight questions and ranges from 0 to 3, with higher levels reflecting greater disability (Pincus et al., 1983).

CRP concentrations were determined at Sasebo Chuo Hospital, and SAA, MMP-3, and RF levels were analyzed by a central laboratory. TNF- α and IL-6 levels were determined using the Bio-Plex kit. All analyses were performed according to the manufacturers' protocols.

Statistical Analysis

The data are presented as the mean \pm standard deviation (SD), except for the data regarding the TNF- α mRNA, TNF- α , SAA, and IgG-RF levels of the mice and the DAS28 and DAS28-related parameters of the RA patients. Groups were compared by one-way analysis of variance (ANOVA) and repeated-measures ANOVA, and differences between groups were determined using Scheffe's or Fisher's protected least significant difference test. We defined 24-h rhythmicity as significant when both cosinor analysis and one-way ANOVA were significant. Cosinor analysis is a natural way of modeling cyclic behavior, and is performed by a single 24-h cosine curve fitting using software (Time Series Analysis Serial Cosinor 6.3).

The MHAQ results are shown as box plots. For each box plot, the median value is represented by the central, horizontal line; the upper and lower quartiles (75 and 25 percentiles) are represented by the upper and lower borders of the box; and the upper and lower extents of the vertical lines extending from the boxes represent the values of the 90th and 10th percentiles, respectively. Leukopenia is shown as each patient's score. Among-group comparisons of MHAQ, RA-related parameters, and leukopenia were made using the Friedman test. Intragroup post hoc testing was performed using the Wilcoxon signed-rank test with Bonferroni's correction after the Friedman test. A probability level of less than .05 was considered to be significant.

RESULTS

Twenty-Four-Hour Rhythms of TNF- α mRNA Expression in Leukocytes of MRL/lpr Mice

TNF- α mRNA levels were detected after total RNA had been extracted from the leukocytes of MRL/lpr mice. There was no significant 24-h rhythm in TNF- α mRNA levels at 10 wks by ANOVA and cosinor analysis. However, at 15 wks, the TNF- α mRNA levels showed a clear 24-h rhythm with higher levels seen at 22 HALO and lower levels observed at 18 HALO (F from ANOVA = 3.55, $p < .05$; p from cosinor = .06; Figure 1).

Influence of MTX Dosing Time on SAA, IgG-RF, and TNF- α Levels in MRL/lpr Mice

MTX was administered three times/wk at 6 or 18 HALO based on the 24-h rhythm of the TNF- α mRNA level (Figure 1). The plasma TNF- α levels did not differ between the control and 6 HALO groups, although they were significantly lower in the 18 HALO group than in the control group ($p < .05$; Figure 2). The SAA concentration in the 18 HALO group was significantly lower than that in the control and 6 HALO groups (vs. control: $p < .01$; vs. 6 HALO: $p < .05$; Figure 2). The groups treated with MTX showed a markedly decreased IgG-RF index compared with the control group (vs. 18 HALO: $p < .05$; Figure 2).

Baseline Characteristics of the Japanese RA Patients

Twenty-two rheumatoid arthritis patients between 41 and 78 yrs of age were enrolled and (77%) received MTX chronotherapy for the entire 3 mos of the study. Their demographic and baseline characteristics are described in Table 1. One of the 17 patients had a DAS28 of > 5.1 , indicating high disease activity, and the other




FIGURE 2. Influence of MTX dosing time on the plasma SAA concentration, IgG-RF index, and TNF- α concentration in MRL/lpr mice. MTX (10 mg/kg) was administered three times/wk for 2 wks (total of 60 mg/kg of MTX) at 6 and 18 HALO. Each value represents the mean and SD of 8 to 15 mice. The TNF- α level was significantly lower in the 18 HALO group than in the control group ($p < .05$). The SAA and IgG-RF levels were significantly decreased in the 18 HALO group compared with the control group ($p < .01$ and $p < .05$).

TABLE 1 Demographic and baseline characteristics of the Japanese RA patients

Number of patients	17
Age (yrs)	61 (41-78) ^a
Sex	5/12 ^b
Body weight (kg)	50.2 (29.8-72.0) ^a
Duration of RA (yrs)	11.8 (2-33) ^a
MTX dose (mg/wk)	6 (4-8) ^c
Disease Activity Score 28	3.83 (3.25-5.30) ^a
Stage	
I	
II	0
III	4
IV	5
	8
Class	
I	1
II	16

^aMean (minimum-maximum).

^bMale/female.

^cMedian (minimum-maximum).

patients had a DAS28 of between 3.2 and 5.1, indicating moderate disease activity.

Influence of MTX Chronotherapy on DAS28, MHAQ, and Adverse Effects in Japanese RA Patients

Table 2 shows the four factors involved in the calculation of the DAS28. The tender joint count decreased slightly after chronotherapy. On the other hand, the swollen joint count decreased markedly from 1.18 at baseline (0 mos) to 0.29 at 3 mos. The CRP level continued to improve throughout the 3-mo study period, and improved by 64.2% after the chronotherapy compared with baseline. VAS, which represents the patient's global assessment of his/her own disease activity, hardly changed despite the patients recognizing the change in the MTX administration method.

The mean DAS28, which is the most commonly used indicator for quantitatively estimating RA symptoms, was 3.65 at 2 mos before chronotherapy and 3.83 at the start of chronotherapy ($p = .279$), and the condition of the RA patients was maintained between moderate and high disease activity. DAS28 was significantly improved after MTX chronotherapy throughout the three clinic visits compared with the baseline (vs. 1 mo: $p = .0197$; 2 mos: $p = .0107$; 3 mos: $p = .0087$ of follow-up;

Figure 3A). On the basis of the EULAR definitions of the treatment response according to DAS28 at 3 mos, seven (41.2%) patients achieved a moderate response, and four (23.5%) patients attained clinical remission (DAS28 < 2.6).

MHAQ, an indicator of functional capacity of RA patients, was markedly decreased by 3 mos of chronotherapy ($p = .0529$; Figure. 3B).

In this study, there were no severe adverse effects.

Influence of MTX Chronotherapy on RA-Related Factors in Japanese RA Patients

Secondary efficacy variables are shown in Table 3. The SAA concentrations gradually decreased over the 3 mos of the chronotherapy, and had improved by 60.6% after the chronotherapy compared with baseline. The other RA-related factors did not change throughout the study.

DISCUSSION

Pain and stiffness show 24-h rhythms with a peak in the early morning in many RA patients (Bellamy et al., 1991, 2002; Kowanko et al., 1982), and the 24-h rhythm of pain and stiffness may play a role in local and systemic inflammatory responses. Herold and Günther (1987) reported that plasma CRP levels, an indicator of inflammatory responses, showed a 24-h rhythm with a peak in the early morning and a trough in the evening in RA patients, which matches the rhythm of pain and stiffness. Proinflammatory cytokines, such as TNF- α and interleukin (IL)-6, are secreted from activated monocytes, and macrophages promote CRP levels in hepatocytes. There were clear 24-h rhythms in the blood concentrations of these cytokines, with higher levels seen in the early morning in RA patients (Crofford et al., 1997; Perry et al., 2009). Since the 24-h rhythms of CRP and cytokines are similar, it is considered that cytokine rhythms contribute to the rhythm of CRP. In our preliminary study using CIA model mice, a significant 24-h rhythm was demonstrated for the concentration of SAA, a marker of the inflammatory response induced by cytokines, and SAA levels were higher at 2 HALO and lower at 22 HALO in mice (data not shown). The plasma TNF- α concentration also showed a 24-h rhythm with a peak at 2 HALO (To et al., 2009). In the current study, we examined TNF- α

TABLE 2 Changes in Japanese RA patients between before and after treatment with MTX chronotherapy

	Time (Mos) before and after MTX chronotherapy					p value
	-2	0	1	2	3	
Tender joint count	9.77 \pm 8.71	10.35 \pm 7.55	8.77 \pm 8.07	8.77 \pm 8.20	8.88 \pm 7.78	N.S.
Swollen joint count	0.65 \pm 1.58	1.18 \pm 1.51	0.18 \pm 0.73	0.41 \pm 1.46	0.29 \pm 0.99	N.S.
CRP (mg/dL)	0.60 \pm 0.94	0.67 \pm 1.29	0.67 \pm 1.11	0.54 \pm 0.94	0.43 \pm 0.71	N.S.
VAS (mm)	41.18 \pm 23.69	35.47 \pm 25.65	32.94 \pm 23.26	32.06 \pm 21.94	32.94 \pm 22.01	N.S.

Data are presented as the mean \pm SD.

© Informa Healthcare USA, Inc.




FIGURE 3. Efficacy and safety during 3 months of MTX treatment in Japanese RA patients. Values are presented as the mean and SD for DAS28 (A) and as a box plot of MHAQ (B) of the 17 patients. (C) Leukopenia □: Grade 0, ▨: Grade 1, ■: Grade 2. The mean DAS28 was 3.65, 3.83, 3.37, 3.33, and 3.31 at -2, 0, 1, 2, and 3 mos, respectively, and DAS28 was significantly improved at 3 mos compared with the baseline (vs. 1 mo: $p = .0197$; 2 mos: $p = .0107$; 3 mos: $p = .0087$).

TABLE 3 Changes in Japanese RA patients after 3 months of treatment with MTX chronotherapy

	Time after MTX chronotherapy (mos)				p-value
	0	1	2	3	
SAA (µg/mL)	13.2 [7.35-24.2]	7.0 [4.6-27.9]	9.5 [4.4-29.1]	8.0 [4.0-31.1]	N.S.
MMP-3 (ng/mL)	81.3 [50.1-151.0]	89.4 [50.5-162.3]	79.9 [54.9-139.3]	83.8 [51.1-163.8]	N.S.
RF (IU/mL)	57.0 [3.5-161.3]	58.0 [2.0-127.0]	54.0 [1.3-202.8]	52.0 [2.3-192.5]	N.S.
TNF-α (pg/mL)	6.44 [2.72-19.8]	6.44 [4.56-61.2]	4.56 [1.13-86.4]	6.44 [3.18-41.0]	N.S.
IL-6 (pg/mL)	7.37 [3.55-33.1]	16.0 [3.47-43.6]	8.40 [4.35-41.1]	9.09 [6.10-29.1]	N.S.

Data are presented as median values [25 percentile-75 percentile].

mRNA expression in MRL/lpr mice. A clear 24-h rhythm, involving higher levels during the late dark phase, was observed for TNF-α mRNA expression. Plasma SAA and TNF-α concentrations also showed 24-h rhythms with peaks at 2 HALO in MRL/lpr mice (data not shown). Therefore, changes in TNF-α concentration may affect the 24-h rhythm of SAA.

In a previous study, our findings with CIA model mice suggested that choosing an optimal dosing time that is associated with the 24-h cycle of TNF-α would lead to the more effective treatment of RA with MTX (To et al., 2009). In this study, in which we used MRL/lpr mice, the 18 HALO group showed significantly reduced plasma SAA levels compared to the control and 6 HALO groups and displayed significantly reduced TNF-α levels compared to the control group. MTX inhibits the production of cytokines by suppressing lymphocyte proliferation (Williams et al., 2001) and TNF-α transcriptional activity (Becker et al., 1998). However, neither the 6 nor 18 HALO group showed a significant decrease in their leukocyte counts compared with the control group (data not shown). Thus, MTX may reduce plasma TNF-

α level by suppressing transcriptional activity rather than suppressing lymphocyte proliferation. In this study, the dosing time-dependent change in the SAA level corresponded to an identical change in TNF-α level. It is likely that the level of SAA is also reduced due to a decrease in TNF-α concentration after MTX administration at 18 HALO. In addition, arthritis and inflammation were reduced in the dark phase (activity span of mice), when plasma TNF-α concentration began to increase, in both the CIA model and MRL/lpr mice. These findings reveal that the therapeutic effects of MTX treatment can be improved by administering MTX when the TNF-α level begins to increase in the blood.

From our studies using RA model animals and the 24-h rhythms of RA patients, we anticipated that higher therapeutic effects compared with those of the current, conventional, treatment schedule could be achieved with chronotherapy in which MTX was administered before bedtime and the dose and number of doses/wk remained the same. Bedtime MTX chronotherapy improved the DAS28 in 14 of 17 patients (82.4%), and the

mean DAS28 value was significantly decreased by 0.460 at 1 mo, 0.506 at 2 mos, and 0.521 at 3 mos after the start of chronotherapy. In particular, despite the dose and number of doses remaining the same, 23.5% of patients achieved clinical remission, and a significant therapeutic effect was observed in 41.2% of patients. Interestingly, four (80%) male and three (25%) female participants achieved a moderate response, with men showing a greater therapeutic effect compared with the women. Although the number of patients was not sufficient in this study, sex differences may lead to variations in the efficacy of the chronotherapy regimen.

DAS28 is calculated from the following four parameters: tender and swollen joint counts, patient's global assessment of his/her disease activity, and CRP concentration. The tender joint count and CRP level changed little throughout this study. On the other hand, the swollen joint count was markedly decreased in all patients after 3 mos of chronotherapy. The patients' global assessments of their disease activity were susceptible to bias because each patient evaluated their own degree of illness. In this study, the patients understood that the method of MTX administration had changed; however, the patients' global assessments of their disease activity did not show significant changes, even though a placebo effect of the chronotherapy was anticipated. Therefore, it was considered that the placebo effect did not contribute to the observed significant decrease in DAS28. It was revealed that MTX chronotherapy improved the functional capacity of RA patients, although we could not clarify the factors responsible for the improvement in MHAQ from the data obtained in this study. Almost all patients had mild leukopenia, although the incidence of leukopenia higher than Grade 1 increased from 11.8% to 23.5% throughout the study. Moreover, there were no severe adverse effects in the 17 patients who completed the trial. From these results, it was demonstrated that MTX chronotherapy is safe and markedly improved disease activity and the functional capacity of RA patients.

Daily variations in the pharmacokinetics of MTX may be involved in the higher therapeutic effect in RA patients brought about by administering MTX at night in the present study. Although the pharmacokinetics of MTX were not determined in this study, it was reported in previous studies that there were no dosing time-dependent changes in MTX pharmacokinetics in patients with cancer (Balis et al., 1989; Robinson et al., 1989). Moreover, no difference was noted in MTX pharmacokinetics according to the clock hour of injection when MTX was administered intramuscularly at 10:00 or 18:00 h to RA patients (Carpentier et al., 1998). In our previous study, CIA mice administered MTX in the rest phase showed a larger area under the plasma concentration-time curve of MTX than mice administered MTX in the active phase (To et al., 2009). However, the daily variations in the pharmacokinetics of MTX were not related to the dosing-time dependency of MTX efficacy. From the

results of our studies and the 24-h cycles of cytokines in RA patients (Crofford et al., 1997; Perry et al., 2009), it is thought that MTX has a significant dosing time-dependent anti-inflammatory action and that this effect may be due to the 24-h rhythms of cytokine levels rather than the pharmacokinetics of MTX.

CONCLUSIONS

The present study, using MRL/lpr mice, revealed that administering MTX at specific times in accordance with the 24-h rhythm of TNF- α leads to decreased inflammatory responses to RA. It was demonstrated in RA patients that disease activity and the patients' functional capacity were improved while safety was maintained when MTX was given once-a-day at bedtime based on our results of the animal study and the 24-h rhythm of TNF- α in RA patients. Choosing an optimal dosing time that is associated with the 24-h rhythms of RA symptoms is, therefore, expected to lead to more effective MTX therapy for RA. We consider that MTX chronotherapy, which showed strong therapeutic effects compared with the current standard treatment in this study, has potential as an RA therapy. To confirm our findings, we are now performing a double-blind, randomized, controlled trial.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Young Scientists (B) (H.T., 17790126) from the Ministry of Education, Culture, Sports, Science, and Technology Japan, The Ministry of Health, Labour, and Welfare of Japan, the Takeda Science Foundation, the Japan Research Foundation for Clinical Pharmacology, and the Policy-based Medical Services Foundation (H.T.).

Declaration of Interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES

- Abe C, Mitsunaga K, Shiokawa Y. (1980). Spontaneous polyarthritis in MRL/l mice. *Ryumachi* 20:233-239.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 31:315-324.
- Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. (1997). The timing of glucocorticoid administration in rheumatoid arthritis. *Ann. Rheum. Dis.* 56:27-31.
- Balis FM, Jeffries SL, Lange B, Murphy RF, Doherty KM, Arndt CA, Luery N, Poplack DG. (1989). Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? *Am. J. Pediatr. Hematol. Oncol.* 11:324-326.
- Becker C, Barbulescu K, Hildner K, Meyer zum Büschenfelde KH, Neurath MF. (1998). Activation and methotrexate-mediated suppression of the TNF α promoter in T cells and macrophages. *Ann. N. Y. Acad. Sci.* 859:219-222.

- Bellamy N, Sothorn RB, Campbell J, Buchanan WW. (1991). Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. *Ann. Rheum. Dis.* 50:243-248.
- Bellamy N, Sothorn RB, Campbell J, Buchanan WW. (2002). Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. *Ann. Rheum. Dis.* 61:1075-1080.
- Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E. (2008). Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. *Lancet* 371:205-214.
- Carpentier N, Bertin P, Marquet P, Sabot C, Bonnet C, Debord J, Lachâtre G, Trèves R. (1998). Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis? *J. Rheumatol.* 25:1270-1275.
- Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. (2002). Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 359:1173-1177.
- Chu CQ, Field M, Feldmann M, Maini RN. (1991). Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. *Arthritis Rheum.* 34:1125-1132.
- Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V. (2001). Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. *Arthritis Rheum.* 44:1984-1992.
- Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL. (1997). Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. *J. Clin. Endocrinol. Metab.* 82:1279-1283.
- D'Alonzo GE, Smolensky MH, Feldman S, Gnosselius Y, Karlsson K. (1995). Bambuterol in the treatment of asthma: a placebo-controlled comparison of once-daily morning vs. evening administration. *Chest* 107:406-412.
- Fransen J, van Riel PL. (2005). The Disease Activity Score and the EULAR response criteria. *Clin. Exp. Rheumatol.* 23:S93-S99.
- Haus E. (2007). Chronobiology in the endocrine system. *Adv. Drug Deliv. Rev.* 59:985-1014.
- Hermida RC, Ayala DE, Mojón Fernández JR. (2010). Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC Study. *Chronobiol. Int.* 27:1629-1651.
- Herold M, Günther R. (1987). Circadian rhythm of C-reactive protein in patients with rheumatoid arthritis. *Prog. Clin. Biol. Res.* 227B:271-279.
- Kodama A, To H, Kinoshita T, Ieiri I, Higuchi S. (2009). Influence of dosing schedules on toxicity and antitumor effects of combined cisplatin and docetaxel treatment in mice. *J. Pharm. Pharmacol.* 61:615-621.
- Koopman WJ, Gay S. (1988). The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. *Scand. J. Rheumatol.* 75 (Suppl):284-289.
- Kowanko IC, Knapp MS, Pownall R, Swannell AJ. (1982). Domiciliary self-measurement in rheumatoid arthritis and the demonstration of circadian rhythmicity. *Ann. Rheum. Dis.* 41:453-455.
- Kremer JM, Phelps CT. (1992). Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. *Arthritis Rheum.* 35:138-145.
- Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. *Lancet* 350:681-686.
- Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. (1997). Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). *Clin. Exp. Immunol.* 107:507-512.
- Mussener A, Litton MJ, Lindroos E, Klareskog L. (1997). Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). *Clin. Exp. Immunol.* 107:485-493.
- Ohdo S, Inoue K, Yukawa E, Higuchi S, Nakano S, Ogawa N. (1997). Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics. *Jpn. J. Pharmacol.* 75:283-290.
- Perry MG, Kirwan JR, Jessop DS, Hunt LP. (2009). Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis. *Ann. Rheum. Dis.* 68:63-68.
- Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. (1983). Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. *Arthritis Rheum.* 26:1346-1353.
- Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. *Chronobiol. Int.* 27:1911-1929.
- Rivard GE, Infante-Rivard C, Dresse MF, Leclerc JM, Champagne J. (1993). Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. *Chronobiol. Int.* 10:201-204.
- Robinson BA, Begg EJ, Colls BM, Jeffery GM, Sharman JR. (1989). Circadian pharmacokinetics of methotrexate. *Cancer Chemother. Pharmacol.* 24:397-399.
- Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. (1991). Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. *Arterioscler. Thromb.* 11:816-826.
- Schmiegelow K, Glomstein A, Kristinsson J, Salmi T, Schröder H, Björk O. (1997). Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). *J. Pediatr. Hematol. Oncol.* 19:102-109.
- Smolensky MH, Lemmer B, Reinberg AE. (2007). Chronobiology and chronotherapy of allergic disease and bronchial asthma. *Adv. Drug Deliv. Rev.* 59:828-851.
- Sulli A, Maestroni GJ, Villaggio B, Hertens E, Craviotto C, Pizzorni C. (2002). Melatonin serum levels in rheumatoid arthritis. *Ann. N. Y. Acad. Sci.* 966:276-283.
- Tabuchi M, To H, Sakaguchi H, Goto N, Takeuchi A, Higuchi S, Ohdo S. (2005). Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. *Cancer Res.* 65:8448-8454.
- To H, Irie S, Tomonari M, Watanabe Y, Kitahara T, Sasaki H. (2009). Therapeutic index of methotrexate depends on circadian cycling of tumor necrosis factor- α in collagen-induced arthritis rats and mice. *J. Pharm. Pharmacol.* 61:1333-1338.
- van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. (1996). Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum.* 39:34-40.
- Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS. (1992). Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. *Arthritis Rheum.* 35:129-137.
- Williams AS, Topley N, Dojcinov S, Richards PJ, Williams BD. (2001). Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. *Rheumatology* 40:375-383.

(記録) 第31回 日本臨床薬理学会年会 2010年12月1~3日 京都
シンポジウム25: 時間疾患の現状

4. 関節リウマチにおける病態の概日リズムと時間薬物療法

藤 秀 人*

1. はじめに

関節リウマチ(RA)は関節滑膜を病変の主座とする進行性の全身性炎症性疾患であるが、発症機序は十分に明らかにされていない。これまでRAの薬物治療は痛みや炎症を抑えるために非ステロイド性抗炎症薬(NSAID)や副腎皮質ホルモン薬、RAの免疫異常を修飾することができるメトトレキサート(MTX)などの疾患修飾性抗リウマチ薬(DMARD)が用いられてきた。また近年では、抗ヒト tumor necrosis factor- α (TNF- α)モノクローナル抗体製剤であるインフリキシマブなどの生物学的製剤の開発により、RAの炎症反応に関与する炎症性サイトカインの作用を効果的に抑制することで、従来の抗リウマチ薬と比較して高い有効性を示すようになった。しかし、生物学的製剤に対する抗体産生や高い薬剤費など多くの問題も山積している。

科学技術の発達によってさまざまなRAの診断法や薬物治療法が開発されており、RA薬物治療は今まさにパラダイムシフトの真っただ中にある。そのため、RA病態の特徴や既存の抗リウマチ薬の特性を理解し、より効果的な治療法を再度検討する良い機会であり、我々はRAの生体リズムという観点からRAの薬物療法について研究を行っている。

2. RAにおける病態の概日リズム

RA患者には他の疾患の患者と異なり、特徴的な症状として朝のこわばりが存在する。朝のこわばりは、深夜から早朝にかけて関節の痛みなどと同時に現れ、日中にはほとんど消失する症状であり¹⁾、多くのRA患者に発現する。これらの原因の詳細は十分に明らかになっていないものの、炎症反応が一部関与していると考えられている。炎症反応の指標であるC-reactive protein (CRP)は、RA患者で関節の痛みやこわばりに沿って早朝に高値、夕方に低値を示す概日リズムを有することが報告されている²⁾。CRPは、炎症性サイトカインによって肝細胞で産生されるが、これらの炎症性サイトカインはRAにおける炎症反応や病態形成に重要な役割を担っていることが知られている。したがって、CRPの概日リズムには、炎症性サイトカインの概日リズムが関与している可能性が考えられる。RA患者

の interleukin-6 (IL-6) や TNF- α などの炎症性サイトカインの血中濃度は、早朝に最高値を示すという概日リズムが認められる³⁾。また、健康人や自己免疫疾患である結合組織症の患者ではIL-6の概日リズムは認められないため、このような概日リズムはRA患者特有の現象であると考えられる³⁾。以上より、こわばりの発症機序に少なからず炎症性サイトカインの日周リズムが関与しているのではないかと考えられている。現在、このような日周リズム形成の制御因子解析が進んでおり、今後の研究の進展に期待したい。

3. これまでのRA治療薬における時間薬物療法

RAにおけるこわばり等の概日リズムの存在は古くからよく知られていたが、このような周期に合わせた薬物療法(時間薬物療法)はほとんど行われていない。Arvidsonらは、合成副腎皮質ホルモン薬であるプレドニゾロンを2:00か7:30に1日1回投薬し、時間治療前後で治療成績を評価した。その結果、2:00投薬群では朝のこわばりなどにおいて7:30投薬群と比較して顕著に軽減できることを明らかにした⁴⁾。しかし、残念なことに現在のRAの薬物治療においてこの時間治療は広く汎用されるには至っていない。その理由としては、有効性は認められるがプレドニゾロンを2:00に服用することが、臨床的には非現実的であったことなどが考えられる。

しかし、2008年にButtgereitらによってRAに対する時間治療の新たな取り組みがLancetに報告された⁵⁾。本試験はプレドニゾンの徐放化製剤による試みであり、深夜服用が回避され寝る前22:00の服用が新製剤によって可能となった。従来の薬剤を用い朝投薬されるグループと新徐放化製剤を用いて寝る前に投薬されるグループの2群に分けられ、二重盲検比較試験が実施された。その結果、新徐放化製剤群が既存薬剤群と比較して有意に朝のこわばりを軽減できることが明らかとなった。

以上のように、RAにおける炎症抑制効果については、ステロイドの時間薬物療法の有用性が証明されている。

4. MTXにおける時間薬物療法の試み

これまでに炎症抑制については、ステロイドによる時間薬物療法の検討がなされているが、現在のRA治療の主要ターゲットとなっている免疫異常の改善を目的としたDMARDや生物学的製剤を対象とした時間薬物療法に関する研究報告は皆無に等しい。そこで、我々は、世界で最

* 富山大学大学院医学薬学研究所 (薬学) 医療薬学研究室
〒930-0194 富山市杉谷2630

も用いられている DMARD の MTX を用いて、RA モデル動物および RA 患者を対象に時間薬物療法の有用性を検証した。

四肢の関節に RA 様の関節炎を発現する II 型コラーゲン感作 (CIA) マウスを対象に、未感作および感作後における血漿中 TNF- α 濃度を測定した結果、CIA 群では、未感作群と比較しいずれの測定時点でも TNF- α 濃度が有意に上昇し、9:00 に最高値、21:00 に最低値を示す有意な日周リズムが発現した (Fig. 1)。次に、この日周リズムを考慮して、TNF- α 濃度が増加し始める 5:00 もしくは低下している 17:00 に MTX を投与して、投薬時刻の違いによる関節炎抑制効果を評価した。その結果、5:00 投薬群において、control 群および 17:00 投薬群と比較して有意に関節炎の増悪を抑制できることが明らかとなった⁶⁾。

以上の RA モデル動物による実験結果と RA 患者の炎症性サイトカインの日周リズムから、MTX の投薬タイミングを推計すると、MTX を夜間 (就寝前) に投薬することで、より効果的な治療成果が得られることが予想された。そこで、RA 患者を対象に MTX の時間薬物療法を行うことで、従来の治療方法と比較し治療効果の向上および副作用の軽減が可能か否かについて評価した。

Fig. 2 には、MTX の時間薬物療法によって得られた代表的な症例の治療成績を示した。RA の臨床指標の 1 つである DAS28 は、時間治療開始前と比較し、時間治療開始後早期より低下し、高い治療効果が認められた。さらに、本試験全体では、17 例の被験者 (男性 5 例、女性 12 例) が 3 カ月間の時間治療を経験し、DAS28 (平均値) は、時間治療開始前と比較し時間治療開始後 3 カ月で有意に減少し、23.5% の被験者が臨床的寛解に到達した。さらに、41.2% の被験者で EULAR 改善基準の中等度反応が認められた。また、試験期間中重篤な副作用は認められなかった。

5. まとめ

RA には、疾患特異的な日周リズムを有しており、これらの制御因子の解明によって、将来より効果的な医薬品の開発につながると期待される。さらに、我々は、動物実験および臨床研究にて、MTX の時間薬物療法の有用性を明らかにした。現在、無作為割付二重盲検比較試験を実施しており、より科学的なエビデンスが構築できることを期待している。以上、今後、いくつかの検討課題は残るものの、比較的安価である MTX を用いた時間薬物療法は、より効果的な RA 薬物療法の提案が可能となり、医療費の削減にもおおいに寄与できると考えられる。

文 献

1) Bellamy N, Sothorn RB, Campbell J, Buchanan WW. Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. *Ann Rheum Dis.* 2002; 61(12): 1075-80.




Fig. 1 RA モデル動物における血中 TNF- α の日周リズムおよび MTX の投薬時刻の違いによる関節炎抑制効果への影響




Fig. 2 MTX の時間薬物療法の一例

2) Herold M, Günther R. Circadian rhythm of C-reactive protein in patients with rheumatoid arthritis. *Prog Clin Biol Res.* 1987; 227B: 271-9.
 3) Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. *Ann Rheum Dis.* 2009; 68(1): 63-8.
 4) Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. *Ann Rheum Dis.* 1997; 56(1): 27-31.
 5) Buttgerit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. *Lancet.* 2008; 371(9608): 205-14.
 6) To H, Irie S, Tomonari M, Watanabe Y, Kitahara T, Sasaki H. Therapeutic index of methotrexate depends on circadian cycling of tumor necrosis factor- α in collagen-induced arthritis rats and mice. *J Pharm Pharmacol.* 2009; 61(10): 1333-8.

